

Andrea Eisen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1455355/publications.pdf>

Version: 2024-02-01

62
papers

1,919
citations

430874

18
h-index

254184

43
g-index

64
all docs

64
docs citations

64
times ranked

3257
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of a decision aid for incidental genomic results, the Genomics ADVISER: protocol for a mixed methods randomised controlled trial. <i>BMJ Open</i> , 2022, 8, e021876.	1.9	22
2	Early Changes in Quantitative Ultrasound Imaging Parameters during Neoadjuvant Chemotherapy to Predict Recurrence in Patients with Locally Advanced Breast Cancer. <i>Cancers</i> , 2022, 14, 1247.	3.7	6
3	Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study. <i>CMAJ Open</i> , 2022, 10, E313-E330.	2.4	2
4	Patient opinions on contralateral prophylactic mastectomy: A patient-driven discussion in need of tuning?. <i>Canadian Journal of Surgery</i> , 2022, 65, E250-E256.	1.2	1
5	Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2022, 29, 2599-2616.	2.2	5
6	Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery. <i>BMJ Open</i> , 2022, 12, e060899.	1.9	10
7	The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 538-538.	1.6	0
8	The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 177-189.	2.5	4
9	Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 2219-2226.	1.5	7
10	Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program. <i>Breast Journal</i> , 2021, 27, 423-431.	1.0	3
11	Abstract PS10-33: Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy. , 2021, , .		0
12	Abstract PS11-20: Radiation therapy (RT) induced toxicity in advanced breast cancer (ABC) patients treated with CDK4/6 inhibitors (CDK4/6is). , 2021, , .		0
13	Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result. <i>Annals of Surgical Oncology</i> , 2021, 28, 4967-4973.	1.5	9
14	The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. <i>Genetics in Medicine</i> , 2021, 23, 1086-1094.	2.4	18
15	Psychological consequences of MRI-based screening among women with strong family histories of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 497-508.	2.5	3
16	Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning. <i>Breast Cancer Research and Treatment</i> , 2021, , 1.	2.5	1
17	Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound. <i>Oncotarget</i> , 2021, 12, 2437-2448.	1.8	8
18	Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program. <i>Journal of the National Cancer Institute</i> , 2020, 112, 136-144.	6.3	55

#	ARTICLE	IF	CITATIONS
19	Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. <i>Genetics in Medicine</i> , 2020, 22, 727-735.	2.4	34
20	Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results. <i>PLoS ONE</i> , 2020, 15, e0236182.	2.5	41
21	Impact of rarity on Canadian oncology health technology assessment and funding. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 404-409.	0.5	1
22	Quality of life drives patients' preferences for secondary findings from genomic sequencing. <i>European Journal of Human Genetics</i> , 2020, 28, 1178-1186.	2.8	14
23	Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi-institutional study. <i>Cancer Medicine</i> , 2020, 9, 5798-5806.	2.8	50
24	Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause. <i>Neurobiology of Aging</i> , 2020, 94, 1-6.	3.1	19
25	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 155-165.	2.5	14
26	Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer. <i>Oncotarget</i> , 2020, 11, 3782-3792.	1.8	24
27	Practitioner Opinion on Contralateral Prophylactic Mastectomy: How Do We Steer a Patient-Driven Discussion?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3489-3494.	1.5	3
28	Development of patient 'profiles' to tailor counseling for incidental genomic sequencing results. <i>European Journal of Human Genetics</i> , 2019, 27, 1008-1017.	2.8	16
29	A response to 'Personalised medicine and population health: breast and ovarian cancer'. <i>Human Genetics</i> , 2019, 138, 287-289.	3.8	14
30	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e031092.	1.9	10
31	<i>A priori</i> prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks. <i>Oncotarget</i> , 2019, 10, 3910-3923.	1.8	16
32	Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. <i>Oncologist</i> , 2018, 23, 768-775.	3.7	19
33	Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 213-223.	1.2	9
34	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	1.9	11
35	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	1.6	131
36	Real-world health services utilisation and outcomes after <i>BRCA1</i> and <i>BRCA2</i> testing in Ontario, Canada: the What Comes Next Cohort Study protocol. <i>BMJ Open</i> , 2018, 8, e025317.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Breast screening for survivors of breast cancer: A systematic review. Preventive Medicine, 2017, 103, 70-75.	3.4	10
38	Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ER1±- breast cancer. PLoS ONE, 2017, 12, e0179223.	2.5	9
39	Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncologyâ€Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology, 2017, 35, 3978-3986.	1.6	127
40	Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology, 2017, 35, 1139-1139.	1.6	0
41	The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. Journal of Genetic Counseling, 2016, 25, 1309-1316.	1.6	24
42	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) â€Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2416-2427.	1.6	112
43	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	1.6	72
44	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology, 2016, 34, 1065-1071.	1.6	65
45	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Supportive Care in Cancer, 2016, 24, 1097-1105.	2.2	81
46	Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer. Journal of Oncology Practice, 2015, 11, 126-132.	2.5	56
47	Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. Breast Cancer Research and Treatment, 2015, 152, 137-145.	2.5	6
48	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation. Journal of Clinical Oncology, 2014, 32, 1547-1553.	1.6	523
49	Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program. Journal of Clinical Oncology, 2014, 32, 2224-2230.	1.6	106
50	Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.. Journal of Clinical Oncology, 2014, 32, 583-583.	1.6	3
51	Utilization of adjuvant trastuzumab for T1a,b N0 HER2+ breast cancer in Ontario.. Journal of Clinical Oncology, 2014, 32, e11569-e11569.	1.6	0
52	The impact of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers.. Journal of Clinical Oncology, 2014, 32, 1507-1507.	1.6	22
53	Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.. Journal of Clinical Oncology, 2014, 32, 1081-1081.	1.6	0
54	Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Canadian Urological Association Journal, 2013, 7, 797.	0.6	12

#	ARTICLE	IF	CITATIONS
55	The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada.. Journal of Clinical Oncology, 2013, 31, 1550-1550.	1.6	0
56	Acute care utilization (ACU) among women receiving adjuvant chemotherapy for early breast cancer (EBC).. Journal of Clinical Oncology, 2012, 30, 65-65.	1.6	4
57	Implementation of a population-based breast screening program for high-risk women in Ontario: The Ontario Breast Screening Program (OBSP) High-Risk Program.. Journal of Clinical Oncology, 2012, 30, e12034-e12034.	1.6	0
58	Variants of uncertain significance in BRCA testing: Impact on risk perception, worry, prevention, and counseling.. Journal of Clinical Oncology, 2012, 30, 1555-1555.	1.6	0
59	Monitoring acute care utilization (ACU) during adjuvant chemotherapy for early breast cancer (EBC) as a measure of quality.. Journal of Clinical Oncology, 2012, 30, 220-220.	1.6	2
60	Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treatment Reviews, 2008, 34, 157-174.	7.7	80
61	Review: breast cancer is associated with a family history of the disease in first degree relatives. Evidence-based Nursing, 2002, 5, 89-89.	0.2	1
62	Effect of culture media on Lactobacillus hydrophobicity and electrophoretic mobility. Microbial Ecology, 1989, 17, 17-25.	2.8	21